Immune checkpoint inhibitors
Pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq) and others. PD-1/PD-L1/CTLA-4 inhibitors transformed oncology — and frequently face appeals for off-label use, combination therapy, and adjuvant settings.
What this class is
Checkpoint inhibitors block inhibitory immune signaling (PD-1, PD-L1, CTLA-4, LAG-3) to enable T-cell anti-tumor activity. Approved across 30+ cancer types with rapidly expanding indications. The class has driven major survival improvements in melanoma, NSCLC, RCC, urothelial, and many other cancers. Off-label use supported by NCCN compendium is common.
Representative drugs
- Pembrolizumab (Keytruda)
- Nivolumab (Opdivo)
- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Ipilimumab (Yervoy)
- Cemiplimab (Libtayo)
Common denial patterns
- Off-label indication denial (NCCN compendium often supports)
- Step therapy requiring chemotherapy first
- Combination-therapy denial (single-agent only)
- Continuation beyond 2 years (some plans cap duration)
Clinical guidelines that win appeals
- NCCN guidelines (per tumor type)
- ASCO/SITC immunotherapy guidelines
Frequently asked questions
What is immune checkpoint inhibitors?
Checkpoint inhibitors block inhibitory immune signaling (PD-1, PD-L1, CTLA-4, LAG-3) to enable T-cell anti-tumor activity. Approved across 30+ cancer types with rapidly expanding indications. The class has driven major survival improvements in melanoma, NSCLC, RCC, urothelial, and many other cancers. Off-label use supported by NCCN compendium is common.
What are the common denial patterns?
Off-label indication denial (NCCN compendium often supports); Step therapy requiring chemotherapy first; Combination-therapy denial (single-agent only); Continuation beyond 2 years (some plans cap duration).
Which clinical guidelines support appeals?
NCCN guidelines (per tumor type); ASCO/SITC immunotherapy guidelines.
Related
- Cancer treatmentsChemo, immunotherapy, CAR-T, proton, PET, off-label per NCCN
- Melanoma & melanoma-immunotherapyKeytruda, Opdivo, Yervoy, Opdualag, BRAF/MEK combos, Amtagvi (TIL), Kimmtrak, Imlygic, neoadjuvant + adjuvant
- Lymphoma & leukemia (heme malignancies)BTKi, BCL2, bispecifics, ADCs, IDH/FLT3 inhibitors, JAK, HMA, TKIs — CLL/HL/NHL/AML/CML/MPN/MDS/ALL/T-cell
- Antifibrotic agentsPirfenidone (Esbriet), nintedanib (Ofev) for idiopathic pulmonary fibrosis (IPF) and progressive pul
- Biologic drugs (mAbs and biosimilars)Monoclonal antibodies and other biologics targeting specific immune or growth pathways. Used in rheu
- BiosimilarsFDA-approved highly-similar versions of reference biologics. Plans frequently require biosimilar use
- Direct oral anticoagulants (DOACs)Apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). Replaced warfar
Appeal a immune checkpoint inhibitors denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com